1. Six more biotechs price public debuts just before the start of the weekend—Surprise pandemic lessons for pharma -- August FDA decisions for Axsome, Sanofi, Merck See more on our front page news
    Dismiss Notice
  2. Do you have general questions about dealing with sexual harassment or discrimination at work? Ask an attorney on this forum.
    Dismiss Notice

Pfizer makes record $36Billion w No Reps or DTC

Discussion in 'Pfizer' started by anonymous, Jun 12, 2021 at 9:23 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    You are correct, pfizer is contractually committed to Exact and one rep can’t get it done. In hindsight the best move from a size standpoint would have been to keep C3 and sack C1, but that decision was made before tany went bust. Hate to see it but can’t say I’m surprised, tany was a crapshoot at best.
     

  2. anonymous

    anonymous Guest

    They could find reps to cover it from any division.
     
  3. anonymous

    anonymous Guest

    True, but why train others when cluster 1 already has the relationships and experience?
     
  4. anonymous

    anonymous Guest

    We are talking about Cologard - it doesn't take much to promote it
     
  5. anonymous

    anonymous Guest

    True, its a Cologard that is zero clinical or technical sell. This product easily can be sold by Publicis or 50k yr CSO with no insurance, 401k or benefit costs.
    Or even sold by Virtual reps since the product has to be ordered & shipped anyway.
    LMAO---Cologard, they didnt seriously put that down did they lol
     
  6. anonymous

    anonymous Guest

    Can’t wait to come back and say I told you so when theses cuts affect everyone. Every division will be reduced and what you say is true about most products, it’s certainly not rocket science! If reps can make it to specialty sales with backgrounds in payroll, copier sales and rental car sales it’s not difficult to replace anyone.
     
  7. anonymous

    anonymous Guest

    Fair point and vaccine div could pick it up… but then they would actually have to go out and make calls!
     
  8. anonymous

    anonymous Guest


    True. But don't you find it hilarious that states are offering millions in lottery and other prizes to get the vax? As if a bunch of people are going to just forget about the risks and "go for the money". Or these articles that "society will reject you" if you don't get it. It's laughably bad. Never have I seen such a poorly orchestrated effort to convince people of something they should not take.
     
  9. anonymous

    anonymous Guest

    Pfizer will have 50% less employees 2022 and 3x more sales.
    We all are toast with Pfizer & Albert's European Service no-sale Model.
    Time to move on
     
  10. anonymous

    anonymous Guest

     
  11. anonymous

    anonymous Guest

    If Albert can avoid international prison.
     
  12. anonymous

    anonymous Guest

    "service no-sale model". What a perfect description of the cluster we're heading towards.
     
  13. anonymous

    anonymous Guest

    It's that elitist New York attitude towards the sales force. They think we are unnecessary and a cost to be managed, as well as a liability.

    Well, we'll just see how many offices roll out the red carpet to talk about "disease state". And fumble around with an app. Most of the offices are wanting us to come back in for face to face appointments. The home office just believe what it wants to believe. Hive Mentality. Just like "everyone needs the vaccine". This is Waco 1993 all over again
     
  14. anonymous

    anonymous Guest

    The same elitist attitude that has caused a 200% increase in violent crime since they "defended the police" is more like it.

    Who didn't see that one coming?
     
  15. anonymous

    anonymous Guest

    I just don’t get it. It’s as if they forgot we have to compete in the marketplace. If you think these other companies are gonna follow our “lead” your crazy. They are actually driven and incentivized to win. I don’t think the shareholders who know what’s going on are gonna be ok with this. We are in the business of growing products and markets. I don’t think this new model does either.
    Less incentive = less growth
    Less growth = less revenue
    Less revenue = less qtr results
    Less qtr results = missed targets
    Missed targets = lower stock $

    Albert… Earth to Albert…

    The windfall form the vaccine was a once in a lifetime gamble. And we gambled with a sure bet… the Fed govt with the panic of a perceived pandemic to approve anything for emergency use and the deep pockets to buy whatever we made at whatever the price.

    They well will run dry… and when it does you will need to rely on the company portfolio to make revenue.

    The same thing happened during the Lipitor years. It carried the company until it didn’t. Then the Toviaz, Exubra, PVC, neutered Chantix of the basement have to make it up and quick.
     
  16. anonymous

    anonymous Guest

    No one is going to follow our lead. No one.
    But remember what Albert wants. He wants a small bio Pharma company. That’s where this is going. Besides the vaccine, I don’t see PFE with billion dollar products anymore. They will focus on small niches
     
  17. anonymous

    anonymous Guest

    What do you think an inside sales representative with broad virtual capabilities will actually do? Part-time or full time? If part time, will they get benefits? Will a sales rep 2.0 be the full time rep that works with the IAT? I think we may leave a lot of lower OD customers or customers not with an IDN to just access resources through the new galaxy portal. Definitely a transformation.
     
  18. anonymous

    anonymous Guest

    Other companies are already doing this model post covid .
    Virtual reps are contracted thru vendor like Publicis & are PT 20-30hrs wk but can reach more doctors PT than live reps do in 2wks.
    Any resources needed or samples is an easy check computer box & send.
    Any in depth clinical info then FMD request is made.
    Any other requests then AM or KAM is requested for follow up.
    It works awesome for other companies & decreases costs while increasing profit margins greatly.
    Surprise Pfizer has not done this years ago
     
  19. anonymous

    anonymous Guest

    You missed it . Pfizer has ALREADY done an 18 month pilot to see if profitable.
    During covid all product reps stayed home and sales increase with large decrease in expenses . So the model has already been proven success for over a year half.
    Reality- Pfe accidently discovered this model reaps greater profits due to not paying 150k per rep, 300k per 2rep terr, and 3k per rep monthly expense account.
    Add it up and its TENS OF MILLIONS A MONTH SPENT THAT NOW WILL BE SAVED FOR BOTTOM LINE.

    I hate it but its new realm of our industry morphing. All industries have went from live to virtual. Look at Insurance, Banking, etc
     
  20. anonymous

    anonymous Guest

    name a pharma company that is doing this